ARNA Arena Pharmaceuticals Inc.

48.81
-0.1  -0%
Previous Close 48.91
Open 48.71
Price To Book 2.03
Market Cap 2,432,215,283
Shares 49,825,162
Volume 251,361
Short Ratio
Av. Daily Volume 428,073
Stock charts supplied by TradingView

NewsSee all news

  1. Arena Pharmaceuticals' Presence at United European Gastroenterology Week Bolsters Commitment to the Gastrointestinal Disease Community

    SAN DIEGO, Oct. 18, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will present new open-label extension data from the Phase 2 OASIS trial for its investigative drug candidate etrasimod, a

  2. Arena Pharmaceuticals Presented New Data from the Phase 2 OASIS trial for Etrasimod at the World Congress of Gastroenterology Meeting

    SAN DIEGO, Calif., Sept. 26, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) presented new data from the Phase 2 OASIS trial for etrasimod, an investigational, once-daily, oral, selective sphingosine

  3. Arena Pharmaceuticals to Present at the Cantor Global Healthcare Conference on October 2

    SAN DIEGO, Sept. 25, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that Amit D. Munshi, President and Chief Executive Officer of Arena, will present a corporate update at the Cantor

  4. Arena Pharmaceuticals to Present New Preclinical Atopic Dermatitis Data for Etrasimod at the European Society for Dermatologic Research Annual Meeting

    SAN DIEGO, Sept. 17, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will present new preclinical data for etrasimod, an investigational, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor

  5. Arena Pharmaceuticals Presented New Patient-Reported Outcomes Data for Olorinab at the European Society of Neurogastroenterology & Motility NeuroGASTRO 2019 Meeting

    SAN DIEGO, Sept. 9, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) presented new patient-reported outcomes data for olorinab, an investigational, oral, peripherally acting, highly-selective, full agonist

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved June 27, 2012.
Lorcaserin
Obesity
Phase 2/3 trial to be initiated 2019.
Olorinab (APD371)
Pain associated with Crohn's disease
Phase 3 commencement of dosing announced June 17, 2019.
Etrasimod - ELEVATE UC 52
Ulcerative colitis
Phase 3 ongoing. Licensed to UTHR November 15, 2018.
Ralinepag
Pulmonary Arterial Hypertension
Phase 2 trial to be initiated 2019.
Etrasimod
Atopic dermatitis (AD)

Latest News

  1. Arena Pharmaceuticals' Presence at United European Gastroenterology Week Bolsters Commitment to the Gastrointestinal Disease Community

    SAN DIEGO, Oct. 18, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will present new open-label extension data from the Phase 2 OASIS trial for its investigative drug candidate etrasimod, a

  2. Arena Pharmaceuticals Presented New Data from the Phase 2 OASIS trial for Etrasimod at the World Congress of Gastroenterology Meeting

    SAN DIEGO, Calif., Sept. 26, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) presented new data from the Phase 2 OASIS trial for etrasimod, an investigational, once-daily, oral, selective sphingosine

  3. Arena Pharmaceuticals to Present at the Cantor Global Healthcare Conference on October 2

    SAN DIEGO, Sept. 25, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that Amit D. Munshi, President and Chief Executive Officer of Arena, will present a corporate update at the Cantor

  4. Arena Pharmaceuticals to Present New Preclinical Atopic Dermatitis Data for Etrasimod at the European Society for Dermatologic Research Annual Meeting

    SAN DIEGO, Sept. 17, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will present new preclinical data for etrasimod, an investigational, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor

  5. Arena Pharmaceuticals Presented New Patient-Reported Outcomes Data for Olorinab at the European Society of Neurogastroenterology & Motility NeuroGASTRO 2019 Meeting

    SAN DIEGO, Sept. 9, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) presented new patient-reported outcomes data for olorinab, an investigational, oral, peripherally acting, highly-selective, full agonist

  6. Arena Pharmaceuticals to Participate in Upcoming Investor Conferences

    SAN DIEGO, Aug. 28, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that members of its senior management team will participate in the upcoming investor conferences: Wells Fargo Global